Healthcare / Drug Manufacturers - Specialty & GenericShanghai
$17.53
-0.99 (-5.35%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 27% · confianza 25%
FCF escenarios
weak_data · normalized FCF $189.8M · quality 57.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
48/100
C
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$8.4B
P/E
18.8x
↓EV/EBITDA
11.7x
↓ROE
12.4%
↑Gross Margin
65.5%
↑Debt/Equity
0.01
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+2.6%
FCF CAGR
—
FCF margin
-1.0%
FCF / Net income
-0.08x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $3.50B · net income $469.4M · FCF $-36.6M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $3.50B | $3.50B | $3.45B | $3.34B | $3.24B |
| Net Income | $469.4M | $469.4M | $488.7M | $488.8M | $438.9M |
| EBITDA | $654.0M | $654.0M | $645.6M | $652.3M | $573.6M |
| EPS | 1.00 | 1.00 | 1.04 | 1.02 | 1.04 |
| Gross Margin | 65.5% | 65.5% | 67.1% | 66.6% | 68.2% |
| Operating Margin | 14.9% | 14.9% | 14.7% | 15.3% | 14.1% |
| Net Margin | 13.4% | 13.4% | 14.2% | 14.6% | 13.5% |
| Balance Sheet | |||||
| Debt/Equity | 0.01 | 0.01 | 0.02 | 0.04 | 0.04 |
| Current Ratio | 3.18 | 3.18 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-36.6M | $-36.6M | $299.2M | $189.8M | $524.4M |
| Returns | |||||
| ROE | 12.4% | 12.4% | 13.8% | 14.1% | 13.8% |
| Valuation | |||||
| P/E | 18.85 | 18.85 | 14.62 | 17.30 | 15.23 |
| EV/EBITDA | 11.65 | 11.65 | 9.95 | 9.28 | 7.44 |
| P/B | 2.18 | 2.18 | 2.01 | 2.44 | 2.11 |
| Growth & Yield | |||||
| Revenue Growth | 1.7% | 1.7% | 3.2% | 3.1% | — |
| EPS Growth | -3.8% | -3.8% | 2.0% | -1.9% | — |
| Dividend Yield | 2.7% | 2.7% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
15.9%
EPS terminal req.
$1.56
Spread vs growth
-19.7%
5Y implied EPS CAGR
13.5%
EPS terminal req.
$1.88
Spread vs growth
-17.3%
10Y implied EPS CAGR
11.7%
EPS terminal req.
$3.03
Spread vs growth
-15.6%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+10.0%
Start / end P/E
15.7x → 17.5x
EPS bridge
1.04 → 1.00
Residual
-0.4%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.